Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer

Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer

US Patent 12128018 · Granted Oct 29, 2024

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses the2025
Dopamine D2 receptor ligands2025
Kinase inhibitors and methods of use thereof2025
Inhibitors of histone deacetylase2023
Dopamine D2 receptor ligands2022
Inhibitors of histone deacetylase2022
Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses the2021
Kinase inhibitors and methods of use thereof2021
Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase in2020
Dopamine D2 receptor ligands2020
Inhibitors of histone deacetylase2020
Dopamine D2 receptor ligands2020